Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy

Journal of Viral Hepatitis

Volumn 20, Issue SUPPL.1, 2013, Pages 65-70

  Liu, M ^a   Cai, H ^a   Yi, W ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

chronic hepatitis B; pregnancy; safety; telbivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ABNORMAL LABORATORY RESULT; ADULT; ANEMIA; ARTICLE; CLEFT LIP; CLEFT PALATE; COMMON COLD; CONGENITAL MALFORMATION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECG ABNORMALITY; ECTOPIC PREGNANCY; EMBRYO DEATH; EXTREMELY LONG UMBILICAL CORD; FEMALE; FOLLOW UP; GESTATIONAL AGE; HEART ARRHYTHMIA; HEPATITIS B; HUMAN; HYDRAMNIOS; HYPEREMESIS GRAVIDARUM; LABOR INDUCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; OLIGOHYDRAMNIOS; PERINATAL PERIOD; PLACENTA ADHERENCE; PLACENTA DISORDER; PLACENTA PREVIA; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UMBILICAL MALFORMATION; VAGINITIS; VERTICAL TRANSMISSION;

ADULT; ANTIVIRAL AGENTS; CHINA; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; THYMIDINE; TREATMENT OUTCOME;

EID: 84874587153     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12066     Document Type: Article

References (36)

1. But DY, Yuen MF, Fung J, Lai CL,. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010; 9: 821-829.
2. Zhang LJ, Wang L,. [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 2009; 17: 561-563.
3. Han GR, Cao MK, Zhao W, et al,. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-1221.
4. Pan CQ, Han GR, Jiang HX, et al,. Telbivudine prevents vertical transmission from HBeAg-Positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 520-526.
5. Han GR, Jiang HX, Wang GJ, et al,. [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. Zhonghua Gan Zang Bing Za Zhi 2012; 20: 201-205.
6. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011; 19: 13-24.
7. Cai HD,. Creatine kinase elevations and myopathy associate with telbivudine and its safe use. Adverse Drug React 2009; 11: 253-256.
8. WHO. Hepatitis B and breastfeeding. 1996-11-22. http://www.who.int/ maternal-child-adolescent/documents/hepb-breastfeeding/en/ (27 January 2012).
9. Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, Kazanji M,. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol 2008; 46: 754-756. (Pubitemid 351231330)
10. Liu CY, Chang NT, Chou P,. Seroprevalence of HBV in immigrant pregnant women and coverage of HBIG vaccine for neonates born to chronically infected immigrant mothers in Hsin-Chu County, Taiwan. Vaccine 2007; 25: 7706-7710. (Pubitemid 47538810)
11. Lin CC, Hsieh HS, Huang YJ, Huang YL, Ku MK, Hung HC,. Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries. BMC Public Health 2008; 8: 49.
12. Jonas MM,. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009; 29 (Suppl 1): 133-139.
13. Soderstrom A, Norkrans G, Lindh M,. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003; 35: 814-819. (Pubitemid 38028916)
14. Leung N,. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int 2009; 3 (Suppl. 1): 24-31.
15. Marcellin P, Asselah T, Boyer N,. Treatment of chronic hepatitis B. J Viral Hepat 2005; 12: 333-345. (Pubitemid 40961472)
16. Shen Q,. One pregnant woman withdrew from lamivudine therapy and died of severe chronic hepatitis B. Strait Pharm J 2005; 17: 182-183.
17. Everett C,. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997; 315 (7099): 32-34. (Pubitemid 27271683)
18. Wu SM, Zhou DR,. Complications of pregnant women infected with hepatitis B virus. Matern Child Health Care China 2005; 20: 2944-2945.
19. Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK,. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 2011; 18: e394-e398.
20. Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y,. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004; 10: 910-912. (Pubitemid 38418373)
21. Safir A, Levy A, Sikuler E, Sheiner E,. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 2010; 30: 765-770.
22. Wang XX,. Outcome of pregnant women infected with hepatitis B virus. Shandong Med J 2006; 46: 61.
23. Antiretroviral PRSC, Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral Pregnancy Registry International. Interim Report for 1 January 1989 through 31 July 2011. 2011-12-1. http://www.apregistry.com/who.htm (28 February 2012).
24. Tse KY, Ho LF, Lao T,. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43: 771-775. (Pubitemid 41414501)
25. Wiseman E, Fraser MA, Holden S, et al,. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-492.
26. Wang JS, Qi ZHU,. Correlative risk factors of chronic hepatitis B virus infection after hepatitis B vaccination in children whose mothers were HBsAg carriers. J Clin Pediatr 2001; 19: 134-136.
27. Wang F, Han GR, Li FZ, Xue YZ,. Correlation between HBV markers and HBV DNA load in pregnant women and intrauterine infection of infants. Mod Med J 2009; 37: 435-437.
28. Yin YZ, Li XM, Chen XW, Hou HY, Shi ZJ,. Study on intrauterine infection of hepatitis B virus. Chin J Birth Health Hered 2006; 14: 48, 88.
29. Xia GL, Gong J, Wang JJ, et al,. Efficacy of recombinant hepatitis B vaccine and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection. Chin J Epidemiol 2003; 24: 362-365.
30. Lobstein S, Faber R, Tillmann HL,. Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. Digestion 2011; 83: 76-82.
31. Wong S, Chan LY, Yu V, Ho L,. Hepatitis B carrier and perinatal outcome in singleton pregnancy. Am J Perinatol 1999; 16: 485-488. (Pubitemid 30196916)
32. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY,. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol 2007; 47: 46-50. (Pubitemid 46830719)
33. To WW, Cheung W, Mok KM,. Hepatitis B surface antigen carrier status and its correlation to gestational hypertension. Aust N Z J Obstet Gynaecol 2003; 43: 119-122. (Pubitemid 36626114)
34. Avila C, Goncalves J,. Creatine kinase elevations during 4-years of continuous telbivudine treatment are transient and not predictive of uncommonly observed muscle-related symptoms. 60th Annual Meeting of the American Association for the Study of Liver Diseases. Poster #472, 2009. Abstr. 472.
35. Lai CL, Gane E, Liaw YF, et al,. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
36. Liaw YF, Gane E, Leung N, et al,. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.